AIM ImmunoTech WKN: A2PREX ISIN: US00901B1052 Forum: Aktien Thema: Hauptdiskussion

https://aimimmuno.irpass.com/Hemispherx-Secures-Corrections-from-Two-Stock-News-Organizations-Related-to-Their-Inaccurate-Reporti The two stock news organizations, Sagient Research and StreetAccount, both misreported that the company was raising $70 million in an Equity Distribution Agreement when, actually, the company was simply renewing a prior EDA that was related to an ATM and making the requisite SEC filings to raise up to $4.5 million under the new EDA, the maximum permitted at this time. In fact, the ATM has not even been used in six months.

https://aimimmuno.irpass.com/Hemispherx-Biopharma-Issues-Clinical-Update-for-Ampligen-Immuno-oncology-Program

Katalysatoren: Ampligen plus Intron A Ovarian cancer Phase 1 interim data to be presented 1Q 2020 Ampligen, Intron A, celecoxib and pembrolizumab Triple-Negative Breast Cancer Phase 1 data due around 2Q 2020. Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 interim data due around 2Q 2020 Ampligen, cisplatin and pembrolizumab Ovarian cancer Phase 2 interim data due around 4Q 2020.

Cash: 9,4Mio$ Burnrate: 848k$ finanziert für 13 Monate (bis Q4 2020) MARKET CAP 3,966,703$ SHARES 8,263,964

https://www.benzinga.com/pressreleases/19/11/ac14821175/correction-aim-immunotech-provides-business-update-for-the-third-quarter-of-2019